Response Tailored Protocol Versus the Fixed 12 Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial

Response Tailored Protocol Versus the Fixed 12 Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial

Background: The most recent European Association for the Study of the Liver (EASL) 2016 Guidelines on treatment of hepatitis C (HCV), allowed for shortening the course of treatment for some subsets of patients with sofosbuvir/ledipasvir and with grazoprevir/elbasvir based on cutoff baseline HCV RNA...

Full description

Bibliographic Details
Main Authors: Mostafa Yakoot, Alaa M. Abdo, Siham Abdel-Rehim, Sherine Helmy
Format: Article
Language:English
Published: Elsevier 2017-07-01
Series:EBioMedicine
Subjects:
Chronic hepatitis C infection
Sofosbuvir
Daclatasvir
Response tailored therapy
Very rapid virologic response
SVR12
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396417302086

Internet

http://www.sciencedirect.com/science/article/pii/S2352396417302086

Similar Items